The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear

Thrombosis Research

Volumn 135, Issue 1, 2015, Pages 155-160

  Loren, Cassandra P ^a,b   Aslan, Joseph E ^a,b   Rigg, Rachel A ^a   Nowak, Marie S ^a,f   Healy, Laura D ^b   Gruber, András ^a,c   Druker, Brian J ^c,d,e   McCarty, Owen J T ^a,b,c  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b Department of Cell and Developmental Biology ^*  (United States)

^c School of Medicine   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f UNIV LILLE   (France)

Author keywords

Chronic Myelogenous Leukemia; Platelets; Thrombosis; Tyrosine Kinase

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; FIBRINOGEN; IMATINIB; NILOTINIB; PONATINIB; THROMBIN; COLLAGEN; IMIDAZOLE DERIVATIVE; PADGEM PROTEIN; PHOSPHATIDYLSERINE; PYRIDAZINE DERIVATIVE; TYROSINE;

ADVERSE OUTCOME; APOPTOSIS; ARTICLE; ASSAY; BIOCHEMICAL ASSAY; CALCIUM SIGNALING; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CELLS BY BODY ANATOMY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; FUNCTIONAL ASSAY; FUNCTIONS OF THE HEMIC, LYMPHATIC AND RETICULOENDOTHELIAL SYSTEMS; GRANULE SECRETION; HUMAN; HUMAN CELL; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHEAR RATE; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBUS; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; PHOSPHORYLATION; PROTEIN MOTIF; SHEAR STRENGTH; THROMBOCYTE;

AMINO ACID MOTIFS; APOPTOSIS; BLOOD PLATELETS; COLLAGEN; ENDOTHELIAL CELLS; FIBRINOGEN; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; P-SELECTIN; PHOSPHATIDYLSERINES; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION; PYRIDAZINES; SHEAR STRENGTH; SIGNAL TRANSDUCTION; TYROSINE;

EID: 84922447674     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.11.009     Document Type: Article

References (35)

1. B.J. Druker Imatinib as a paradigm of targeted therapies Adv Cancer Res 91 2004 1 30
2. T. O'Hare, D.K. Walters, E.P. Stoffregen, T. Jia, P.W. Manley, and J. Mestan In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 2005 4500 4505
3. E. Weisberg, P.W. Manley, W. Breitenstein, J. Bruggen, S.W. Cowan-Jacob, and A. Ray Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2005 129 141
4. E. Weisberg, P. Manley, J. Mestan, S. Cowan-Jacob, A. Ray, and J.D. Griffin AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL Br J Cancer 94 2006 1765 1769
5. W.S. Huang, C.A. Metcalf, R. Sundaramoorthi, Y. Wang, D. Zou, and R.M. Thomas Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant J Med Chem 53 2010 4701 4719
6. J.M. Gozgit, M.J. Wong, S. Wardwell, J.W. Tyner, M.M. Loriaux, and Q.K. Mohemmad Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies Mol Cancer Ther 10 2011 1028 1035
7. P. Neelakantan, D. Marin, M. Laffan, J. Goldman, J. Apperley, and D. Milojkovic Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy Haematologica 97 2012 1444
8. A. Quintas-Cardama, X. Han, H. Kantarjian, and J. Cortes Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia Blood 114 2009 261 263
9. M.H. Cohen, G. Williams, J.R. Johnson, J. Duan, J. Gobburu, and A. Rahman Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia Clin Cancer Res 8 2002 935 942
10. M.D. Dalzell Ponatinib pulled off market over safety issues Manag Care 22 2013 42 43
11. M.S. Mathisen, H.M. Kantarjian, J. Cortes, and E.J. Jabbour Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia Blood Rev 2014 2014
12. J.E. Aslan, G.W. Tormoen, C.P. Loren, J. Pang, and O.J. McCarty S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation Blood 118 2011 3129 3136
13. J.E. Aslan, A. Itakura, J.M. Gertz, and O.J. McCarty Platelet shape change and spreading Methods Mol Biol 788 2012 91 100
14. J.E. Aslan, A. Itakura, K.M. Haley, G.W. Tormoen, C.P. Loren, and S.M. Baker p21 activated kinase signaling coordinates glycoprotein receptor VI-mediated platelet aggregation, lamellipodia formation, and aggregate stability under shear Arterioscler Thromb Vasc Biol 33 2013 1544 1551
15. S.P. Watson, J.M. Auger, O.J. McCarty, and A.C. Pearce GPVI and integrin alphaIIb beta3 signaling in platelets J Thromb Haemost 3 2005 1752 1762
16. T. O'Hare, W.C. Shakespeare, X. Zhu, C.A. Eide, V.M. Rivera, and F. Wang AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 16 2009 401 412
17. W. Xu, A. Doshi, M. Lei, M.J. Eck, and S.C. Harrison Crystal structures of c-Src reveal features of its autoinhibitory mechanism Mol Cell 3 1999 629 638
18. K.V. Gleixner, B. Peter, K. Blatt, V. Suppan, A. Reiter, and D. Radia Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V Haematologica 98 2013 1450 1457
19. O. Hantschel, F. Grebien, and G. Superti-Furga The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL Cancer Res 72 2012 4890 4895
20. L.S. Quek, J. Bolen, and S.P. Watson A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen Curr Biol 8 1998 1137 1140
21. S. Severin, C.A. Nash, J. Mori, Y. Zhao, C. Abram, and C.A. Lowell Distinct and overlapping functional roles of Src family kinases in mouse platelets J Thromb Haemost 10 2012 1631 1645
22. H. Park, M.I. Wahl, D.E. Afar, C.W. Turck, D.J. Rawlings, and C. Tam Regulation of Btk function by a major autophosphorylation site within the SH3 domain Immunity 4 1996 515 525
23. J.M. Pasquet, B. Gross, L. Quek, N. Asazuma, W. Zhang, and C.L. Sommers LAT is required for tyrosine phosphorylation of phospholipase cgamma2 and platelet activation by the collagen receptor GPVI Mol Cell Biol 19 1999 8326 8334
24. M. Merten, and P. Thiagarajan P-selectin expression on platelets determines size and stability of platelet aggregates Circulation 102 2000 1931 1936
25. B.R. Lentz Exposure of platelet membrane phosphatidylserine regulates blood coagulation Prog Lipid Res 42 2003 423 438
26. I. Sadovnik, E. Lierman, B. Peter, H. Herrmann, V. Suppan, and G. Stefanzl Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA Exp Hematol 42 2014 282 293 (e4)
27. M.P. Gratacap, V. Martin, M.C. Valera, S. Allart, C. Garcia, and P. Sie The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo Blood 114 2009 1884 1892
28. A. Mazharian, C. Ghevaert, L. Zhang, S. Massberg, and S.P. Watson Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation Blood 117 2011 5198 5206
29. S. Okabe, T. Tauchi, Y. Tanaka, and K. Ohyashiki Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells Biochem Biophys Res Commun 435 2013 506 511
30. B.E. Tourdot, M.K. Brenner, K.C. Keough, T. Holyst, P.J. Newman, and D.K. Newman Immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated inhibitory signaling is regulated by sequential phosphorylation mediated by distinct nonreceptor tyrosine kinases: a case study involving PECAM-1 Biochemistry 52 2013 2597 2608
31. R. Chari, S. Kim, S. Murugappan, A. Sanjay, J.L. Daniel, and S.P. Kunapuli Lyn, PKC-delta, SHIP-1 interactions regulate GPVI-mediated platelet-dense granule secretion Blood 114 2009 3056 3063
32. Z. Ming, Y. Hu, J. Xiang, P. Polewski, P.J. Newman, and D.K. Newman Lyn and PECAM-1 function as interdependent inhibitors of platelet aggregation Blood 117 2011 3903 3906
33. I. Pabinger, J. Thaler, and C. Ay Biomarkers for prediction of venous thromboembolism in cancer Blood 122 2013 2011 2018
34. D.L. Hanna, R.H. White, and T. Wun Biomolecular markers of cancer-associated thromboembolism Crit Rev Oncol Hematol 88 2013 19 29
35. M.A. Berny-Lang, J.E. Aslan, G.W. Tormoen, I.A. Patel, P.E. Bock, and A. Gruber Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells Phys Biol 8 2011 015014